Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235235 · ClinicalTrials.gov registry record
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
A clinical trial, sponsored by Hoosier Cancer Research Network.
- Terminated
- Registry status
- 80
- Enrollment target
NCT00235235 is a clinical trial that was terminated before completion, run by Hoosier Cancer Research Network. The registered enrollment target is 80 participants.
The verdict
NCT00235235 was terminated before completion, sponsored by Hoosier Cancer Research Network.
- TERMINATED
- Registry status
- 80 participants
- Enrollment target
Study Summary
The proposed trial provides a unique opportunity in that it combines genomic, proteomic, and pharmacogenomic assessments in patients receiving the most commonly used chemotherapies for advanced breast cancer. To date no other trial has analyzed gene and protein expression at the same time points in the same patient, combined with clinical outcome. Similar to previous attempts to predict response based on expression of a single gene or protein, the researchers expect that neither genomic or proteomic profiling alone will be sufficient to optimize therapy. Rather, the researchers expect an iterative process that combines information gleaned from both platforms, modified to avoid toxicity based on pharmacogenomics.
Interventions
- DRUG Cyclophosphamide
- PROCEDURE Biopsy
- DRUG Doxorubicin
- PROCEDURE Serum Collection
- PROCEDURE Urine Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-09 |
| Est. Completion | 2010-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00235235
The ClinicalTrials.gov registry entry for NCT00235235 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoosier Cancer Research Network, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00235235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00235235 about?
NCT00235235 is a clinical study titled "A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer". The proposed trial provides a unique opportunity in that it combines genomic, proteomic, and pharmacogenomic assessments in patients receiving the most commonly used chemotherapies for advanced breast cancer. To date no other trial has analyzed gene and protein expression at the same time points in ...
What is the current status of trial NCT00235235?
This trial is currently terminated. The enrollment target is 80 participants. The study started on 2005-09. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00235235?
The interventions under investigation include: Cyclophosphamide (DRUG), Biopsy (PROCEDURE), Doxorubicin (DRUG), Serum Collection (PROCEDURE), Urine Collection (PROCEDURE).
Who is sponsoring clinical trial NCT00235235?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.